ALKA-SELTZER ORIGINAL

Alka-Seltzer Original tablets may always be dissolved in a glass of water prior to oral administration. The tablets dissolve more quickly in warm water. The dose in adults, elderly and children aged 16 years and over, is two tablets in water.

The dose may be repeated every four hours, as required, with a maximum of four dosages in 24 hours. These dosages should not be continued for more than three days without consulting a physician. The stated dose must not be exceeded. g.

for Kawasaki’s disease).

The listed adverse drug reactions are based on spontaneous reports, thus an organization according to CIOMS III categories of frequency is not possible. Blood and lymphatic system disorders Increased risk of bleeding (due to effect on platelet aggregation).

In the context of bleeding: haemorrhagic anaemia, iron deficiency anaemia with the respective laboratory and clinical signs and symptoms. In the context of glucose-6-phosphate dehydrogenase (G6PD) deficiency: haemolysis, haemolytic anaemia Immune system disorders Hypersensitivity, drug hypersensitivity, allergic edema and angioedema, anaphylactic reaction, anaphylactic shock with respective laboratory and clinical manifestations Nervous system disorders Cerebral and intracranial haemorrhage, dizziness Ear and labyrinth disorders Tinnitus Cardiac disorders In the context of severe allergic reactions: cardio-respiratory distress Vascular disorders Haemorrhage, operative haemorrhage, haematoma, muscle haemorrhage Respiratory, thoracic and mediastinal disorders Epistaxis, analgesic asthma syndrome, rhinitis, nasal congestion, bronchospasm Gastrointestinal disorders Dyspepsia, gastrointestinal pain, abdominal pain, gingival bleeding, gastrointestinal inflammation, gastrointestinal ulcer, gastrointestinal haemorrhage, gastrointestinal ulcer perforation with the respective laboratory and clinical signs and symptoms, nausea, diarrhoea, vomiting Hepatobiliary disorders Liver disorder, transaminases increased Skin and subcutaneous tissue disorders Rash, urticaria, pruritus, severe skin reactions Renal and urinary disorders Impaired renal function Injury, poisoning and procedural complications See overdose section Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

g. renal vascular disease, congestive heart failure, volume depletion, major surgery, sepsis or major haemorrhagic events), since acetylsalicylic acid may further increase the risk of renal impairment, impaired hepatic function. Acetylsalicylic acid may precipitate bronchospasm and induce asthma attacks or other hypersensitivity reactions.

Risk factors are pre-existing asthma, hay fever, nasal polyps, or chronic respiratory disease. g. cutaneous reactions, itching, urticaria) to other substances. g. dental extractions). At low doses, acetylsalicylic acid reduces the excretion of uric acid.

This can possibly trigger gout attacks in predisposed patients. There is a possible association between aspirin and Reye’s syndrome when given to children. Reye’s syndrome is a very rare disease, which affects the brain, and liver, and can be fatal.

g. Kawasaki’s disease). In patients suffering from severe glucose-6-phosphate dehydrogenase (G6PD) deficiency, acetylsalicylic acid may induce haemolysis or haemolytic anaemia. Factors that may increase the risk of haemolysis are high dosage, fever, or acute infections, for example.

85% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

g. asthma, rhinitis, urticaria) induced by the administration of salicylates or substances with a similar action, notably non-steroidal anti-inflammatory drugs,  active or a history of peptic ulcers,  haemorrhagic diathesis,  severe renal failure,  severe hepatic failure,  severe cardiac failure,  in combination with methotrexate at doses of 15 mg/week or more (see interactions with other medicinal products and other forms of interaction),  third trimester of pregnancy,  breastfeeding.